This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic ...

With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests2 across a wide-range of disease areas including ...

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for ...

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form ...

Roche launched a relatively more compact addition to its mainstay cobas molecular diagnostic lineup with instruments that aim to bring automated testing to laboratories of all sizes. Roche is ...

The new molecular test broadens Roche’s sexual-health diagnostics portfolio by enabling simultaneous detection of bacterial vaginosis and Candida vaginitis from a single sample. ・Roche (USOTC:RHHBY) ...

Roche Diagnostics has launched its new molecular laboratory instrument, the cobas ® 5800 System, in the UK. Through improved automation the new system can help raise testing volumes, improve ...

Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types. The cobas HDV ...